Aclaris Therapeutics (ACRS) AI Stock Analysis

• Market Cap: $441.38M
• Dividend Yield: N/A
• Average Volume (3M): 1.11M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.41
• Revenue Growth: -41.87%
• EPS Growth: -165.76%
• Country: US
• Employees: 61
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.16
• Shares Outstanding: 120,595,190
• 10 Day Avg. Volume: 1,094,755
• 30 Day Avg. Volume: 1,106,653
• PEG Ratio: 0.08
• Price to Book (P/B): 3.58
• Price to Sales (P/S): 47.18
• P/FCF Ratio: -7.84
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 54.12
• Enterprise Value/Gross Profit: 73.85
• Enterprise Value/Ebitda: -6.18
• 1Y Price Target: $11.33
• Price Target Upside: 192.10% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -0.64
• Revenue Forecast (FY): $5.97M

• Rating: 52 Neutral
• Price Target: $4.00 ▲(3.09% Upside)
• Action: Reiterated Date: 03/12/26
• Date: Action: Reiterated 03/12/26

The score is held back mainly by weak financial performance: sharply declining revenue, very large losses, and persistent negative free cash flow. Technicals are relatively supportive with the stock trading above key moving averages, while valuation is constrained by negative earnings and no dividend. Corporate events add a modest positive from improved funding access and early clinical progress, tempered by dilution.

Positive Factors

Minimal debt / low leverage

Aclaris has essentially no reported debt, reducing interest burden and financial distress risk. Low leverage preserves strategic optionality to fund R&D or partner programs with equity or collaborations, supporting longer-term execution flexibility despite operating losses.

Demonstrated access to capital

Two recent equity raises and sustained institutional participation signal continued market access and investor confidence from life-science-focused funds. Reliable funding channels materially extend runway and enable planned clinical milestones and partnership discussions over the coming 2-6 months.

Positive ATI-052 Phase 1a data and expanded pipeline

Favorable first-in-human data for ATI-052 with long half-life and strong PD supports infrequent dosing and competitive differentiation. Coupled with a broadened inflammation/immunology pipeline, these structural advancements create multiple clinical value inflection points if later trials confirm efficacy and safety.

Negative Factors

Sharp revenue decline

Top-line has contracted materially, reflecting limited commercial revenue or one-time payments. A shrinking revenue base increases reliance on financing and partnerships to fund operations and makes profitability and margin recovery highly uncertain absent new revenue streams or successful late-stage readouts.

Persistent negative cash flow / high burn

Consistent negative operating and free cash flow (~-$47M TTM) shows structural cash burn. Ongoing R&D and trial spends will keep funding needs high, making operational continuity contingent on capital markets or partnerships and increasing execution risk over the medium term.

Contracted equity and dilution risk

Declining shareholder equity alongside repeated equity raises indicates dilution and erosion of book value. Continued reliance on dilutive financings to fund burn can reduce per-share economics for investors and signal limited internal cash generation to support growth without further issuance.

Aclaris Therapeutics Business Overview & Revenue Model

Company Description

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

How the Company Makes Money

null

Aclaris Therapeutics Financial Statement Overview

Summary

Overall financial profile is high risk: TTM revenue fell sharply (~50% YoY) and profitability remains deeply negative (net margin ~-900%). Cash flow is consistently negative with sizable burn (TTM operating cash flow and free cash flow both about -$47M). The balance sheet is a partial offset with essentially no debt, but equity has contracted meaningfully alongside ongoing losses.

Income Statement

TTM (Trailing-Twelve-Months) revenue fell sharply to about $7.8M (down ~50% vs. the prior year), highlighting a weakening top-line trajectory. Profitability remains deeply negative: net margin is around -900% and operating results are still heavily loss-making, despite a positive gross profit in TTM. While losses have narrowed versus 2024 on an absolute basis (net loss ~$65M vs. ~$132M), the business is still far from break-even and results are highly sensitive to revenue volatility.

Balance Sheet

The balance sheet is a relative strength: reported total debt is essentially zero in the most recent periods (and minimal historically), reducing financial risk and interest burden. However, equity and assets have contracted meaningfully (equity down to ~$103M in TTM from ~$156M in 2024), consistent with ongoing losses and cash burn. Returns on equity remain strongly negative, indicating shareholders are being diluted/eroded by persistent operating deficits even with low leverage.

Cash Flow

Cash generation remains weak with negative operating cash flow and negative free cash flow in every period shown; TTM operating cash flow is about -$47M and free cash flow about -$47M. Free cash flow also deteriorated versus the prior year (TTM down ~40% in growth terms), implying an accelerating cash burn profile. The one positive is that free cash flow is roughly in line with reported net losses (notably in TTM), suggesting limited non-cash earnings quality distortion—but the overall funding need remains substantial.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.83M	18.72M	31.25M	29.75M	6.76M
Gross Profit	5.74M	15.93M	13.17M	17.79M	2.05M
EBITDA	-64.47M	-51.72M	-115.45M	-84.36M	-64.46M
Net Income	-64.92M	-132.06M	-88.48M	-86.91M	-90.86M
Balance Sheet
Total Assets	160.46M	220.33M	197.41M	254.60M	251.21M
Cash, Cash Equivalents and Short-Term Investments	90.75M	113.59M	119.11M	217.57M	191.41M
Total Debt	2.12M	0.00	426.00K	684.00K	693.00K
Total Liabilities	57.38M	64.77M	40.23M	56.98M	53.87M
Stockholders Equity	103.08M	155.55M	157.18M	197.62M	197.34M
Cash Flow
Free Cash Flow	-47.11M	-20.20M	-79.63M	-68.17M	-52.44M
Operating Cash Flow	-47.11M	-20.07M	-78.33M	-67.57M	-52.13M
Investing Cash Flow	48.37M	-69.77M	46.22M	12.63M	-167.63M
Financing Cash Flow	-5.86M	74.54M	26.71M	72.87M	225.05M

Aclaris Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.88
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACRS, the sentiment is Positive. The current price of 3.88 is above the 20-day moving average (MA) of 3.34, above the 50-day MA of 3.36, and above the 200-day MA of 2.38, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 57.02 is Neutral, neither overbought nor oversold. The STOCH value of 84.97 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACRS.

Aclaris Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACRS	52 Neutral	$441.38M	-4.66	-113.23%	―	-41.87%	-165.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
STIM	47 Neutral	$93.52M	-2.33	-138.87%	―	78.62%	32.39%
SERA	47 Neutral	$73.72M	-4.40	-47.69%	―	1.06%	22.41%
MDXH	46 Neutral	$161.86M	-5.33	516.59%	―	21.68%	58.30%
NOTV	44 Neutral	$12.93M	-0.17	-44.77%	―	4.54%	47.11%
XGN	44 Neutral	$72.64M	-6.57	-126.62%	―	14.08%	1.34%

Aclaris Therapeutics Corporate Events

Aclaris Therapeutics Raises $20 Million in Equity Financing

On March 10, 2026, Aclaris Therapeutics, Inc. raised $20 million in gross proceeds through the sale of 5.7 million shares of its common stock under an amended and restated sales agreement with Leerink Partners and Cantor Fitzgerald. The shares were purchased by prominent life sciences investors Frazier Life Sciences, Kalehua Capital and Adage Capital Partners LP, underscoring continued institutional support and providing additional capital to fund the company’s operations and strategic initiatives.

The transaction, executed pursuant to an at-the-market style equity arrangement updated in February 2025, diversified Aclaris’s shareholder base with sector-focused funds and reinforced its access to public equity markets. This equity raise, while dilutive to existing shareholders, strengthened the company’s balance sheet and may enhance its flexibility in advancing its development programs and pursuing its business objectives within the competitive biopharmaceutical landscape.

The most recent analyst rating on (ACRS) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Aclaris Therapeutics stock, see the ACRS Stock Forecast page.

Aclaris Therapeutics Raises Capital via Institutional Stock Sale

From March 2 to March 9, 2026, Aclaris Therapeutics, Inc. sold 12.7 million shares of its common stock, raising gross proceeds of $39.8 million under its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. The shares were purchased by institutional investors, including Deep Track Capital, signaling continued access to capital markets and institutional support that may strengthen the company’s financial position and flexibility for its operations.

The company characterized this disclosure as furnished rather than filed under U.S. securities laws, limiting the applicability of certain Exchange Act liabilities to the information provided. This technical designation underscores that the capital raise was reported for informational purposes while managing the legal exposure typically associated with formal filings, a point relevant to regulatory and compliance stakeholders.

The most recent analyst rating on (ACRS) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Aclaris Therapeutics stock, see the ACRS Stock Forecast page.

Aclaris Therapeutics Expands Inflammation and Immunology Pipeline Strategy

On January 12, 2026, Aclaris Therapeutics updated its corporate overview presentation to highlight a broadened inflammation and immunology pipeline and a strategy centered on innovative oral and bispecific or multispecific antibody therapies for Th1-, Th2- and Th17-mediated diseases. The presentation underscored four anticipated clinical programs and multiple potential value inflection points in 2026, including progress on bosakitug (ATI-045), ATI-052, ATI-2138, next-generation ITK-selective inhibitors, and bispecific antibodies across dermatology, respiratory and gastrointestinal indications, while emphasizing prudent capital management and the need for strategic partnerships, moves that could materially influence its competitive position and long-term growth prospects in large, underserved markets.

The most recent analyst rating on (ACRS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Aclaris Therapeutics stock, see the ACRS Stock Forecast page.

Aclaris advances ATI-052 after positive Phase 1a results

On January 6, 2026, Aclaris Therapeutics reported positive interim data from a first-in-human Phase 1a single and multiple ascending dose trial of its bispecific antibody ATI-052 in healthy adults, showing the drug was well tolerated up to 720 mg with mostly mild, self-resolving injection site reactions and no serious adverse events or discontinuations. The study demonstrated a potentially best-in-class pharmacokinetic profile with an effective half-life of at least 26 days and dose-proportional exposure, alongside robust pharmacodynamic effects including strong target engagement and sustained inhibition of key inflammatory markers at low doses, supporting the possibility of dosing as infrequently as once every three months. On the back of these results, the company moved to rapidly advance ATI-052’s development, planning imminent initiation of Phase 1b proof-of-concept trials in atopic dermatitis and asthma in the first quarter of 2026, with top-line data expected in the second half of 2026 and a Phase 2b trial in atopic dermatitis slated to start in the same period, potentially strengthening Aclaris’s position in the competitive immunology and allergy market if later-stage trials confirm these early findings.

The most recent analyst rating on (ACRS) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Aclaris Therapeutics stock, see the ACRS Stock Forecast page.